A 12-Month Multicentre, Randomised, Double-Blind, Placebo-Controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors.
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2010
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Acronyms RIALTO
- Sponsors Sanofi
- 07 Jul 2009 Actual patient number (174) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Additional trial acronym RIALTO identified as reported by ClinicalTrials.gov.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.